Navigation Links
Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
Date:12/3/2007

STUDIO CITY, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced its presence at the XIII World Congress on Cardiac Pacing and Electrophysiology to be held December 2-6, 2007 in Rome, Italy. At the Congress, Dr. Muricio Arruda, who has been testing Signalife's wireless Fidelity 400 Intracardiac Monitor at the Electrophysiology Laboratories of the Cleveland Clinic Heart Center, will present a prototoype of the Fidelity 400 Intracardiac Monitor to selected participants. The Signalife Fidelity 400 Intracardiac Monitor applies Signalife's award-winning proprietary physiological signal acquisition and amplification technology to read intracardiac signals procured from intracardiac catheter products. An intracardiac catheter is a flexible tube that is inserted through a vein in the leg and fed into the heart. The catheter is equipped with electrodes which allows the signal to be recorded within the heart, and the catheter data is transmitted to a monitor, which allows the physician to evaluate cardiac function, including arrhythmia, or irregular heartbeat. These readings are beneficial in that they measure signals directly from the heart, as opposed to signals read from the surface of the body as is typical in the ordinary application of heart monitors.

The mission of the World Congress of Cardiac Pacing and Electrophysiology is to provide an education forum, underlining evidence-based clinical practices in the field of arrhythmology for clinical cardiologists and electrophysiologists. The Congress will also highlight the latest and most advanced topics in invasive electrophysiology and cardiac pacing, giving leading electrophysiologists the opportunity to demonstrate and discuss new diagnostic and therapeutic strategies.

Dr. Arruda, a faculty member of the XIII World Congress, stated: "I am very happy and impressed with the progress made by the Signalife research & development team on the Fidelity 400 multi- channel, wireless ECG/IC system from the initial results presented at the 2006 Heart and Rhythm Society Conference. The main objective and benefit of the novel system is to offer a technology that overcomes problems presently associated with recordings of surface ECG and intracardiac signals during electrophysiological studies".

Dr. Budimir Drakulic, Signalife's Chief Technology Officer, stated: "We have applied Signalife's patented signal processing technology to intracardiac signals with the same success realized with ambulatory ECG recordings and are looking forward to further development of this technology. We intend to file this one-of-a-kind intra-cardiac monitor for FDA approval shortly."

Dr Lowell Harmison, Signalife's President, states that "this technology application will allow us to get new data concerning a host of electrophysiological changes in the heart that were not impossible to be obtained before. Our electrocardiography technology is opening new opportunities for medical research and clinical findings based on getting a more accurate and definitive ECG signal in the catheterization lab and surgery as well as under conditions of stress and a spectrum of ambulatory conditions. It is becoming a powerful new tool for cardiac monitoring and for improved cardiac care."

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Provides Corporate Update
2. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Signalife Receives Another $3.3 Million Sales Orders
6. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
7. Signalife Continues to Procure Purchase Orders, Revenues
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. U.S. Patent 7,299,083 Awarded to Signalife
10. Medpace Strengthens Presence in Central Europe
11. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Should antibiotic bone cement products be used ... infection after standard total hip or knee replacement surgery? ... have been fielding a lot lately. "Antibiotic ... --> "Antibiotic Bone Cement: Fighting ... --> While there isn,t a simple answer, ECRI ...
(Date:2/8/2016)... 2016 Novan, Inc. today announced that Director Robert ... Directors of Novan. In addition, Robert Keegan has been ... Carolina . --> North Carolina ... received a total of $32.8 million of net proceeds in a ... network originating throughout the Research Triangle area of North ...
(Date:2/8/2016)... ... , ... Information Management Services ( IMS ) is pleased to announce a ... technical foundation and is so significant it was endowed with a new name, BSI ... search results, a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral ... will present information about the company,s programs at the BIOCEO conference ... York City . --> --> ... EST. Registered attendees can request a one on one meeting through ... --> New York City . ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
(Date:1/27/2016)... 27, 2016  Rite Track, Inc. a leading semiconductor ... West Chester, Ohio announced today the acquisition ... based in Austin, Texas , will ... provide modifications, installations and technical support offerings for TEL ... PLUS, commented, "PLUS has provided world class service including ...
Breaking Biology News(10 mins):